Quoin Pharmaceuticals Ltd ADR (QNRX)

$4.29 -0.14 (-3.16%)
Market Cap 8.90M
Revenue (ttm) 0.00
Net Income (ttm) -15.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 42,400
Avg Vol 119,386
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 17%
Beta 1.56
Analysts Strong Sell
Price Target $29.67

Company Profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 980 4182
Address:
42127 Pleasant Forest Court, Ashburn, United States
TraderBuckNKY
TraderBuckNKY Jun. 4 at 1:45 PM
$QNRX did nothing for the s/p...? What gives?...
0 · Reply
DARKP00L
DARKP00L Jun. 4 at 1:29 PM
$QNRX 08:48 on Jun. 04 2026 Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton Syndrome #tradeideas
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:17 AM
$BJDX $CHNR $QNRX $WGRX ticket
0 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:21 AM
$BMNR $HITI $EOSE $QNRX SN
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 10:22 PM
$QNRX $WGRX $ADVB $CLIR things
0 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 3 at 7:32 PM
$QNRX $BYND $%
0 · Reply
BillionaireMotion
BillionaireMotion May. 29 at 5:42 PM
$QNRX $BYND Can double
0 · Reply
FinanceLegacy
FinanceLegacy May. 29 at 4:57 PM
$CYAB cybersecurity playy can go parabolic lets gooooo same setup as $HUBC $PRZO $QNRX $IMCC we banked massively on 🤩🤩
0 · Reply
MilsLearning
MilsLearning May. 22 at 9:36 AM
$QNRX
0 · Reply
BillionaireMotion
BillionaireMotion May. 21 at 10:34 PM
You miss all the insane 400%+ squeezers ??! Put ticker EZRA on watch ! Starting to make a move now and breakout! Looks like shorts could get squeezed hard.. EZRA has 515k shares remaining to the public only . We saw a mini spike earlier.. Would not be shocked at all if it runs soon. Always try to buy early before the crowd does 🚀 💎 $QNRX $BJDX $BDRX $HITI weed one
0 · Reply
Latest News on QNRX
Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan

2026-06-04T12:45:47.000Z - 14 hours ago

Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Jun 4, 2026, 8:30 AM EDT - 14 hours ago

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals submits QRX003 IND application to FDA

2026-06-02T14:36:20.000Z - 2 days ago

Quoin Pharmaceuticals submits QRX003 IND application to FDA

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

Jun 2, 2026, 8:30 AM EDT - 2 days ago

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 9:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Earnings release: Q1 2026

Quoin Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 9:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Quarterly report: Q1 2026

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-04T10:11:14.000Z - 4 weeks ago

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 30, 2026, 8:30 AM EDT - 5 weeks ago

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Apr 28, 2026, 12:02 PM EDT - 5 weeks ago

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

2026-04-28T13:41:57.000Z - 5 weeks ago

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Apr 28, 2026, 8:30 AM EDT - 5 weeks ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global

2026-03-27T11:06:44.000Z - 2 months ago

Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global

Quoin Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Annual report: Q4 2025

Quoin Pharmaceuticals Earnings release: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Earnings release: Q4 2025

Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-03-25T13:40:52.000Z - 2 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

2026-03-25T13:35:56.000Z - 2 months ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA

2026-03-25T12:55:48.000Z - 2 months ago

Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

Mar 25, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Slides: Corporate presentation

Mar 25, 2026, 7:00 AM EDT - 2 months ago

Quoin Pharmaceuticals Slides: Corporate presentation

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

Mar 19, 2026, 8:30 AM EDT - 2 months ago

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

2026-03-11T12:38:45.000Z - 3 months ago

Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Mar 11, 2026, 8:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program

2026-02-26T13:53:53.000Z - 3 months ago

Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program

Quoin Pharmaceuticals Ltd – ADR trading resumes

2026-02-17T15:25:48.000Z - 3 months ago

Quoin Pharmaceuticals Ltd – ADR trading resumes

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

2026-02-17T15:15:27.000Z - 3 months ago

Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause

Quoin announces submission to Japanese MHLW for ODD for QRX003

2026-01-27T13:36:50.000Z - 4 months ago

Quoin announces submission to Japanese MHLW for ODD for QRX003

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Jan 27, 2026, 8:30 AM EST - 4 months ago

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin files Breakthrough Medicine Designation with SFDA for QRX003

2026-01-20T13:46:13.000Z - 4 months ago

Quoin files Breakthrough Medicine Designation with SFDA for QRX003

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Jan 20, 2026, 8:30 AM EST - 4 months ago

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Quoin announces achievement of rapamycin target loadings

2025-11-11T13:35:24.000Z - 7 months ago

Quoin announces achievement of rapamycin target loadings

Quoin Pharmaceuticals files to sell 10.05M ADSs for holders

2025-11-07T21:55:18.000Z - 7 months ago

Quoin Pharmaceuticals files to sell 10.05M ADSs for holders

Quoin Pharmaceuticals Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 7 months ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Quoin Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 7 months ago

Quoin Pharmaceuticals Quarterly report: Q3 2025

Quoin Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 9:30 AM EST - 7 months ago

Quoin Pharmaceuticals Earnings release: Q3 2025

Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year

2025-11-06T13:36:03.000Z - 7 months ago

Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year

Quoin Pharmaceuticals sees cash runway into 2027

2025-11-06T13:35:38.000Z - 7 months ago

Quoin Pharmaceuticals sees cash runway into 2027

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 7 months ago

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Quoin recruits three additional patients to Netherton Syndrome study

2025-10-28T12:40:50.000Z - 7 months ago

Quoin recruits three additional patients to Netherton Syndrome study

Quoin Pharmaceuticals announces FDA granted ODD to QRX003

2025-10-21T12:35:22.000Z - 8 months ago

Quoin Pharmaceuticals announces FDA granted ODD to QRX003

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Oct 10, 2025, 9:24 AM EDT - 8 months ago

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Sep 9, 2025, 8:30 AM EDT - 9 months ago

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Aug 18, 2025, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Aug 12, 2025, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Quoin Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Quoin Pharmaceuticals Quarterly report: Q2 2025

Quoin Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Quoin Pharmaceuticals Earnings release: Q2 2025

Quoin Pharmaceuticals Provides Product Portfolio Update

Jul 29, 2025, 8:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Provides Product Portfolio Update

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jul 17, 2025, 8:00 AM EDT - 11 months ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Jul 7, 2025, 8:00 AM EDT - 11 months ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Slides: Corporate Presentation

Jun 13, 2025, 4:27 PM EDT - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 14, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Quoin Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Earnings release: Q1 2025

Quoin Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q1 2025

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 31, 2025, 4:18 AM EDT - 1 year ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Mar 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 27, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 25, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Feb 4, 2025, 7:30 AM EST - 1 year ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 23, 2025, 5:30 AM EST - 1 year ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Jan 6, 2025, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 20, 2024, 9:20 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 19, 2024, 8:00 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024, 8:18 AM EST - 1 year ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Registration statement: Registration Filing

Dec 18, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Quoin Pharmaceuticals Slides: Corporate Presentation

Dec 16, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Slides: Corporate Presentation

Quoin Pharmaceuticals Registration statement: Registration Filing

Dec 11, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Quoin Pharmaceuticals Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q3 2024

Quoin Pharmaceuticals Earnings release: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Quoin Pharmaceuticals Earnings release: Q3 2024

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Quoin Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Quarterly report: Q2 2024

Quoin Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Earnings release: Q2 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 4:10 PM EDT - 2 years ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 25, 2024, 4:05 PM EDT - 2 years ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Quarterly report: Q1 2024

Quoin Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q1 2024

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:10 PM EDT - 2 years ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings Call Transcript: Q4 2023

Quoin Pharmaceuticals Annual report: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Annual report: Q4 2023

Quoin Pharmaceuticals Earnings release: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q4 2023

Quoin Pharmaceuticals Annual report: Q4 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Annual report: Q4 2024

Quoin Pharmaceuticals Earnings release: Q4 2024

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Earnings release: Q4 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Mar 7, 2024, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Feb 27, 2024, 7:00 AM EST - 2 years ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Feb 14, 2024, 9:00 AM EST - 2 years ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Quoin Pharmaceuticals Registration statement: Registration Filing

Feb 13, 2024, 7:00 AM EST - 2 years ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2024, 7:00 AM EST - 2 years ago

Quoin Pharmaceuticals Proxy statement: Proxy Filing

Quoin Pharmaceuticals Registration statement: Registration Filing

Feb 12, 2024, 7:00 AM EST - 2 years ago

Quoin Pharmaceuticals Registration statement: Registration Filing

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Dec 13, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 9, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Earnings Call Transcript: Q3 2023

Quoin Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Quarterly report: Q3 2023

Quoin Pharmaceuticals Earnings release: Q3 2023

Nov 9, 2023, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Earnings release: Q3 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 8, 2023, 5:46 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

TraderBuckNKY
TraderBuckNKY Jun. 4 at 1:45 PM
$QNRX did nothing for the s/p...? What gives?...
0 · Reply
DARKP00L
DARKP00L Jun. 4 at 1:29 PM
$QNRX 08:48 on Jun. 04 2026 Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton Syndrome #tradeideas
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:17 AM
$BJDX $CHNR $QNRX $WGRX ticket
0 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:21 AM
$BMNR $HITI $EOSE $QNRX SN
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 10:22 PM
$QNRX $WGRX $ADVB $CLIR things
0 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 3 at 7:32 PM
$QNRX $BYND $%
0 · Reply
BillionaireMotion
BillionaireMotion May. 29 at 5:42 PM
$QNRX $BYND Can double
0 · Reply
FinanceLegacy
FinanceLegacy May. 29 at 4:57 PM
$CYAB cybersecurity playy can go parabolic lets gooooo same setup as $HUBC $PRZO $QNRX $IMCC we banked massively on 🤩🤩
0 · Reply
MilsLearning
MilsLearning May. 22 at 9:36 AM
$QNRX
0 · Reply
BillionaireMotion
BillionaireMotion May. 21 at 10:34 PM
You miss all the insane 400%+ squeezers ??! Put ticker EZRA on watch ! Starting to make a move now and breakout! Looks like shorts could get squeezed hard.. EZRA has 515k shares remaining to the public only . We saw a mini spike earlier.. Would not be shocked at all if it runs soon. Always try to buy early before the crowd does 🚀 💎 $QNRX $BJDX $BDRX $HITI weed one
0 · Reply
BillionaireMotion
BillionaireMotion May. 21 at 7:08 PM
$QNRX Took a position on EZRA at these levels. Looking for a massive run. Spiked crazy pre-market. EZRA has now only 515k shares free float. Which makes it very squeezable! They had great news this week, Would not be shocked if it runs wild soon. All of these low floats are running 200%+ recently! Started to see some bulls accumulating EZRA now..
0 · Reply
revuelto
revuelto May. 19 at 3:16 PM
$QNRX its management have a history…market is judging it as if its bound to fail…good in a way for those buying here as they will get the kicks from any run on even an ounce of positive news…but what if the market is pricing it exactly the way it should be? Story of any nano cap bio i guess, wild price swings 😀
0 · Reply
TraderBuckNKY
TraderBuckNKY May. 18 at 1:04 PM
$QNRX ... any Ebola possibilities here?...
1 · Reply
ZacksSCR
ZacksSCR May. 12 at 9:15 PM
$QNRX: Targeting Completing Recruitment for NS Trial by YE26 https://buff.ly/qben8oW
0 · Reply
revuelto
revuelto May. 11 at 4:00 PM
$QNRX will need to wait for the def 14a in q3 but I would assume the free float is now much closer to the shares outstanding ads count, ~2m.……trading is thin right now but once someone starts aggressively slapping the bid, this will move exponentially higher..classic illiquid nanocap dynamics 😀
1 · Reply
TraderBuckNKY
TraderBuckNKY May. 11 at 2:51 PM
$QNRX something positive is brewing....
0 · Reply
revuelto
revuelto May. 11 at 1:58 PM
$QNRX trading as if this is a lost cause…but for how much longer? The stage it’s at isn’t exactly extremely bullish but it’s not extremely bearish either…so yeah, I am staying in 😀..
0 · Reply
Telll
Telll May. 7 at 1:10 PM
$QNRX 🙌🏻 https://investors.quoinpharma.com/node/10231/pdf
0 · Reply
SuperGreenToday
SuperGreenToday May. 7 at 10:56 AM
$QNRX
0 · Reply
revuelto
revuelto May. 5 at 9:57 PM
$QNRX a ‘run’ here would be perfect…it’s got all the classic ingredients...the science checks out…now I see whether management surprises us for once or sticks to form😀
0 · Reply
V2IcedPriate
V2IcedPriate May. 1 at 11:57 PM
$QNRX known runner
0 · Reply
V2IcedPriate
V2IcedPriate May. 1 at 11:56 PM
$QNRX
0 · Reply